IceCure Medical Ltd. has promoted Shay Levav to Chief Operating Officer as the company prepares to expand its commercial activities in the U.S. following the recent FDA clearance of its ProSense® system for low risk breast cancer. Levav will continue to oversee Regulatory Affairs, Quality Assurance, and Clinical Affairs in his new role.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IceCure Medical Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN19929) on November 10, 2025, and is solely responsible for the information contained therein.